Home » Stocks » Athenex

Athenex, Inc. (ATNX)

Stock Price: $12.08 USD -0.52 (-4.13%)
Updated Jul 16, 2020 12:01 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 986.03M
Revenue (ttm) 122.86M
Net Income (ttm) -107.95M
Shares Out 81.63M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $12.08
Previous Close $12.60
Change ($) -0.52
Change (%) -4.13%
Day's Open 12.46
Day's Range 12.07 - 12.46
Day's Volume 87,498
52-Week Range 5.63 - 20.27

More Stats

Market Cap 986.03M
Enterprise Value 936.11M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 81.63M
Float 46.82M
EPS (basic) -1.39
EPS (diluted) -1.39
FCF / Share -1.53
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.58M
Short Ratio 14.27
Short % of Float 15.60%
Beta 1.04
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.03
PB Ratio 5.73
Revenue 122.86M
Operating Income -100.85M
Net Income -107.95M
Free Cash Flow -124.42M
Net Cash 49.92M
Net Cash / Share 0.61
Gross Margin -40.18%
Operating Margin -82.09%
Profit Margin -87.90%
FCF Margin -101.28%
ROA -24.29%
ROE -85.91%
ROIC -72.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$28.03*
(132.04% upside)
Low
15.3
Current: 12.08
High
38.0
Target: 28.03
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue10189.1038.0420.5513.94
Revenue Growth13.61%134.21%85.12%47.38%-
Gross Profit31.6142.1012.920.830.79
Operating Income-120-127-110-85.75-50.71
Net Income-124-117-131-87.72-50.60
Shares Outstanding74.0564.5949.9640.1233.77
Earnings Per Share-1.67-1.82-2.63-2.19-1.50
Operating Cash Flow-97.46-109-81.51-47.87-33.76
Capital Expenditures-13.57-3.32-5.44-1.15-3.31
Free Cash Flow-111-113-86.95-49.02-37.07
Cash & Equivalents16110751.0441.7554.03
Total Debt63.8846.761.9833.013.65
Net Cash / Debt96.9460.6649.068.7450.38
Assets310231140106120
Liabilities13410249.6971.2220.90
Book Value18813990.0433.8198.58
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Athenex, Inc.
Country United States
Employees 574
CEO Yiu Nam Lau

Stock Information

Ticker Symbol ATNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ATNX
IPO Date June 14, 2017

Description

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.